Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading about AbbVie鈥檚 sprawling drug pipeline, patent cliffs, and FDA milestones inside a 300-page 10-K can be daunting. Add tables that track Humira biosimilar erosion and footnotes on Allergan-related intangibles, and even seasoned analysts look for help. That鈥檚 why this page exists鈥�AbbVie SEC filings explained simply, without losing the critical details investors need.
Stock Titan鈥檚 AI breaks down every document the moment it hits EDGAR. Whether you need an AbbVie annual report 10-K simplified for pipeline probability math, an AbbVie quarterly earnings report 10-Q filing summarizing segment sales, or an AbbVie 8-K material events explained after a surprise FDA letter, our platform highlights the numbers and narrative that move ABBV shares. AG真人官方-time alerts surface AbbVie Form 4 insider transactions real-time, turning raw data into context within minutes. The same engine powers deeper AbbVie earnings report filing analysis that links management commentary to model-ready metrics.
Investors often ask how to spot patent-expiration risk or track Botox Aesthetics revenue in SEC disclosures. Here鈥檚 where to look:
- Form 4鈥攎辞苍颈迟辞谤 AbbVie insider trading Form 4 transactions and AbbVie executive stock transactions Form 4 before key drug launches.
- 10-Q / 10-K鈥攃ompare R&D spend vs. pipeline progress with AI-generated heat maps.
- DEF 14A鈥攖丑别 AbbVie proxy statement executive compensation reveals incentives tied to new-drug approvals.
From 鈥渦nderstanding AbbVie SEC documents with AI鈥� to setting custom alerts for upcoming trials, Stock Titan equips you to act on the data, not just read it.
Schedule 13G Overview 鈥� The Vanguard Group & Ralliant Corp (RAL)
On 30 June 2025, The Vanguard Group filed a Schedule 13G reporting passive beneficial ownership of Ralliant Corp鈥檚 common stock. Vanguard now controls 13,174,096 shares, representing 11.65 % of RAL鈥檚 outstanding shares. The filing is made under Rule 13d-1(b) because Vanguard is an SEC-registered investment adviser ("IA").
Voting vs. dispositive authority
- Sole voting power: 0 shares
- Shared voting power: 49,118 shares
- Sole dispositive power: 12,898,650 shares
- Shared dispositive power: 275,446 shares
While Vanguard has virtually no direct voting power, it retains the right to dispose of nearly all of the reported shares, indicating the holding is spread across indexed and managed funds that delegate voting to third parties or follow fund-level policies.
Implications for investors
- Crossing the 10 % threshold makes Vanguard a significant institutional holder, potentially increasing RAL鈥檚 visibility among passive and ETF-tracking investors.
- The passive 13G filing (rather than an activist 13D) signals no intention to influence control or strategy.
- Concentrated ownership may add liquidity support but could create share-supply risk if Vanguard trims its position.
The certification confirms the stake was acquired in the ordinary course of business and not to influence management. The document is signed by Ashley Grim, Head of Global Fund Administration, on 7 July 2025.
Harte Hanks (HHS) has filed a Form 4 revealing that General Counsel Robert T. Wyman received 25,000 restricted stock units (RSUs) on 2 June 2025 at a reference price of $4.55 per share. The RSUs vest in three equal annual tranches on each anniversary of the grant date, encouraging long-term retention and alignment with shareholder interests.
After the award, Wyman reports 27,217 directly held common shares and 33,334 unvested RSUs鈥�25,000 from the new 2025 grant plus 8,334 remaining from a 12,500-share grant made on 4 Mar 2024. The RSUs are held indirectly by the company until they vest, and no derivative securities, option exercises or open-market transactions were disclosed.
The filing represents routine executive equity compensation rather than an outright purchase. Immediate cash outlay is zero, and the incremental dilution from 25,000 shares is expected to be negligible relative to the company鈥檚 total share count. While the grant reinforces incentive alignment, it is unlikely to have a material impact on Harte Hanks鈥� near-term valuation or trading dynamics.
Potbelly Corporation (PBPB) 鈥� Form 4 filing: President & CEO Robert D. Wright reported three Code F transactions on 06/30/2025. Code F denotes shares surrendered to the issuer to cover tax obligations arising from the vesting of previously granted restricted stock units (RSUs).
- Shares withheld: 1,004, 537 and 641, totaling 2,182 common shares at an indicated price of $12.25.
- Post-transaction ownership: 780,254 common shares held directly.
- Context: The surrendered shares represent tax-related withholding, not open-market sales, and reduce Mr. Wright鈥檚 stake by a small fraction relative to his overall holdings.
No derivative security activity was reported, and there were no purchases or sales for investment purposes. The filing is routine and conveys minimal impact on Potbelly鈥檚 share-count or insider ownership profile.
Potbelly Corporation (PBPB) 鈥� Form 4 filing: President & CEO Robert D. Wright reported three Code F transactions on 06/30/2025. Code F denotes shares surrendered to the issuer to cover tax obligations arising from the vesting of previously granted restricted stock units (RSUs).
- Shares withheld: 1,004, 537 and 641, totaling 2,182 common shares at an indicated price of $12.25.
- Post-transaction ownership: 780,254 common shares held directly.
- Context: The surrendered shares represent tax-related withholding, not open-market sales, and reduce Mr. Wright鈥檚 stake by a small fraction relative to his overall holdings.
No derivative security activity was reported, and there were no purchases or sales for investment purposes. The filing is routine and conveys minimal impact on Potbelly鈥檚 share-count or insider ownership profile.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
What is AbbVie Inc.?
Which therapeutic areas does AbbVie focus on?
How does AbbVie generate revenue?
What differentiates AbbVie in the pharmaceutical industry?
How does AbbVie approach research and development?
What are some key products or portfolios of AbbVie?
How does AbbVie maintain quality and compliance?
What makes AbbVie a reliable choice for investors?
